Abstract Endometrial cancer is frequent in MMRmutation carriers. Estimates of annual incidence rates have, however, been based on retrospective studies. The purpose of our study was to prospectively assess the incidence rates of endometrial cancer in women either having a mutation in one of the four MMR genes MLH1, MSH2, MSH6 or PMS2 (Mut?) or belonging to families meeting the revised Amsterdam criteria in which no MMR mutation was detected (Ams?). Eight out of 80 Mut? (10%) contracted invasive endometrial cancer compared to 1/171 (0.6%) of the Ams? (P = 0.0006). The annual incidence rate after first control was 2.5% in Mut? and 0.2% in Ams?. Two of the 8 Mut? women (25%) had synchronous gynaecological tumours. The numbers included did not allow for firm conclusions, but the results are in keeping with the notion that the inherited colon-endometrial cancer syndrome may be restricted to carriers of MMR mutations.
Introduction
Colorectal cancer (CRC) may cluster in families [1] . Adult onset familial CRC has been given various names. Henry Lynch developed the concepts of Lynch syndromes I and II. Lynch I refers to families with CRC only (hereditary site-specific colon cancer). Lynch II includes other forms of cancer, including endometrial cancer [2] . For research purposes, the Lynch syndromes were denoted hereditary non-polyposis colon cancer (HNPCC), and criteria were developed to perform studies to identify the genes. These criteria were referred to as the Amsterdam criteria (AMSI) [3] . They were adopted as clinical criteria by some [4] . The Bethesda criteria were another set of criteria developed for this purpose [5] . A high penetrance of endometrial cancer in HNPCC kindreds, was confirmed following the identification of the MMR genes MLH1 and MSH2, and it became clear that mutations in these genes were associated not only with endometrial cancer, but with other cancers also, for example of the small bowel, ureter, and renal pelvis [6] . Later, it was reported that for families with predominantly endometrial cancers the cancers were caused by MSH6 mutations [7] . The AMSI criteria were therefore revised to include these cancers (AMSII criteria), aiming at identifying HNPCC with better sensitivity [8] .
It has become clear that not all families fulfilling the AMSI or AMSII criteria have a detectable MMR mutation [9] [10] [11] , and it has been reported that cancer risk is different in families with an MMR mutation than in families fulfilling the Amsterdam criteria but without indication of an MMR mutation [12, 13] . Lindor et al. [12] reported lower annual incidence of CRC, later onset of CRC, and a lower incidence of other malignancies in AMSI families in which testing of tumour tissue for microsatellite instability (MSI) showed no abnormalities, compared to AMSI families in which MSI indicated the presence of an MMR mutation. We have recently reported the prospective observation that all CRC kindred had the same annual incidences of tubular adenomas, whereas in the MMR-mutation carriers the adenomas progress more rapidly to severe dysplasia or cancer [13] . Restricting the term ''Lynch syndrome'' to MMR-mutation carriers has recently been suggested [14] .
Most information on cancer risk in families fulfilling the Amsterdam criteria with and without a detected MMR mutation is based on retrospective reports, making it difficult to validate colon and endometrial cancer incidence rates, as they are selection criteria for the families examined. In the last 19 years we have identified more than 1,000 persons at risk of CRC based on family history and followed them prospectively in Norway. Similar activity has been undertaken in the last seven years in Spain. We here report prospectively observed endometrial cancers in the combined series. (IHC) . All tumours examined were tested for MSI but not with IHC for PMS2 in Spain, and all tumours were tested with IHC for PMS2 but not all for MSI in Norway. Preferably, an affected person who would be an obligate carrier if the family were to have a dominantly inherited disorder, and/or the youngest affected, was examined. If the test result was normal and the patient examined was not a potential obligate carrier, we tested another person also to exclude the possibility that the initially tested person was a phenocopy. Following a positive IHC or MSI result, we performed germline MMR gene analysis on a blood sample from the individual, from a (potential) obligate carrier in the family, or-if no such sample was available-we tested healthy relatives [13, 15] .
Material and methods

This
All genetic testing was done diagnostically at national and international approved laboratories. The genetic testing done for research purposes in Norway has been reported previously [15, 16] .
The retrospective findings in the same Norwegian families have been reported previously [6, 7, 17, 18] .
The Spanish series included 64 consecutive unrelated families fulfilling Amsterdam criteria. Unpublished retrospective analysis of these families showed that endometrial cancer was significantly more common in Mut? families (cumulative risk of endometrial cancer was 0.263 and 0.067 respectively, P \ 0.001).
The women in this study were healthy at inclusion, with no previous history of endometrial or ovarian cancer, and 25 years of age or older. The series were for this study grouped as follows:
I. Mutation carriers (Mut?): In kindred with a demonstrated pathogenic MMR mutation, all women considered to be at risk were offered predictive testing.
Only those women carrying a mutation were included in the study. II. Amsterdam criteria II (Ams?): Female first-degree relatives of affected in families meeting the AMSII criteria, but where no mutation had been found in the family.
Women in both groups were referred to annual (Spain) or biannual (Norway) ultrasound (US) of the endometrium from the age of 25 onwards. The examination included transvaginal ultrasound of the endometrium and measurement of the thickness of the endometrial wall, ultrasound of the ovaries, and a cervical smear. Abnormal findings were classified as precancers (complex endometrial hyperplasia) or infiltrating cancers.
All records for women meeting the above criteria were updated to include either a physical examination with the method mentioned, or a self-declaration of having experienced no pelvic cancer in 2006. Observation years were calculated from the date of first examination to the date of last examination.
Eighty Mut? and 171 Ams? women were identified. They were followed for a total of 242.7 and 475.6 years, respectively. Of the Mut? women, 36 were from Norway and 44 from Spain. Of the Ams? women 144 were from Norway and 27 from Spain (Table 1) .
About 12 women in the Mut? group had only one control. Mean follow-up time counting all women was 3.0 years (range: 0-9.1) and 3.6 years (range: 0.4-9.1) counting only those with more than one control. In the Ams? group 48 women had only one control. Mean follow-up time counting all was 2.8 years (range: 0-8.5) and 3.9 years (range: 0.2-8.5) counting those with more than one control. Mean age at first control was 39.0 years (range: 25-65) in the Mut? group and 45.3 years (range: 25-79) in the Ams? group.
In Norway, all activity was part of the public health system and all information was kept in computerized medical files. In Spain, local ethics committees cleared the study protocol and all patients gave written consent to participate. No data containing names were exported from either system.
Statistics
Annual incidence rates were calculated as events observed after first control/follow-up years. Ninety-five percent confidence intervals were calculated on the basis of assumed Poisson distributions. Two-by-two tables were assessed by Fischer's exact P. The Kaplan-Meier algorithm was used to consider survival functions. The software packages Oracle 10g, Excel 5.0, Systat 10, and StatExact4 were used.
Numbers of cancers expected to occur by chance were derived from The Cancer Registry of Norway [19] , employing age-specific annual incidence rates and multiplying by follow-up years for each individual patient observed. The calculations were done both when considering the age for the observation period to be age at first control, and the age at last control. The numbers of cancer expected was estimated to be the mean of the two. Observed and expected number of cases were compared with v 2 statistics.
Results
Of the 80 Mut? women included in the study, eight were diagnosed with invasive endometrial cancer and two with precancer. Three had also had previous cancer diagnoses, one breast cancer at 40 years of age and two colon cancers 36 and 52 years of age. In addition, two of the patients with invasive cancer (25%) had synchronous additional gynaecological tumours. Thus, not counting the breast cancer, but including a borderline ovarian tumour, 4/8 (50%) in this group had, at the end of the study, had more than one tumour associated with the MMR mutation. Two of the invasive cancers were endocervical endometrioid adenocarcinomas. One of these had spread and the patient died 27 months after diagnosis. The other patient was diagnosed with a concurrent ovarian cancer with spread to local lymph nodes. No other cancers had spread and no other relapses were observed in the Mut? group. Seven of the eight cancers were interval cancers diagnosed as a result of bleeding. Prevalence of cancer at first control was 2/80 (2.5%).
In the Ams? group, one cancer and one precancer were detected. Both were diagnosed in screening, and the cancer had not spread. IHC of the invasive cancer showed the presence of gene product from MLH1, MSH2, MSH6, and PMS2. IHC of tumour tissue from an affected relative of the woman diagnosed with complex hyperplasia also showed the presence of gene product from the MMR genes. The findings are detailed in Tables 1 and 2 . When comparing the two groups we found that in the Mut? group 8/80 (10%) (95% CI 4.4%-19.8%) had infiltrating cancers versus 1/171 (0.6%) (95% CI 0%-3.3%) in the Ams? group (P = 0.0006).
Annual incidence of endometrial cancer detected after the first round was 6/242, 7 (2.5%) (95% CI 0.9%-5.4%) in the Mut? group compared with 1/475,6 (0.2%) (95%CI 0%-1.2%) in the Ams? group. Kaplan-Meier analysis including only invasive endometrial cancer gave a fiveyear event-free survival of 85.7% (standard error 0.063) in the Mut? group and 97.5% (standard error 0.025) in the Ams? group (P = 0.01), and an annual incidence rate of 2.9% and 0.5% in the two groups (Fig. 1) . Expected number of endometrial cancers was 0.03, compared with six observed (p ( 0.01) in the Mut? group. Expected number of cancers was 0.15 compared with 1 observed in the Ams? group.
Discussion
Based on our prospective findings we conclude that increased risk of endometrial cancer may be restricted to families with a detectable MMR mutation. We do not know the cause(s) of cancer in the AMSII kindred without a demonstrable mutation, but our results indicate that they, as a group, have a lower risk of endometrial cancer than mutation-carrying women. This supports the suggestion that the term ''Lynch syndrome'' be restricted to MMRmutation carriers [14] .
One may bear in mind, however, that the Ams? group were first-degree relatives of affected women. If the kindred had a dominantly inherited disorder they began life with an a priori risk of 50% of being mutation carriers, i.e., our results do not exclude the possibility that a fraction of the Ams? kindred have a dominantly inherited disorder not yet identified.
Prospective series are usually considered obligatory to arrive at conclusions in oncology. The reason why prospective series are not numerous on this subject is that they are hard to conduct. To increase number of events we combined the series reported. To make our observations available, we report our findings. The numbers provided do not justify sophisticated analyses and the significance values should be interpreted with caution while we await results from similar prospective series comparing mutation carriers and non-carriers.
Our Ams? group includes women from nine Norwegian families for which IHC of one affected relative showed lack of MMR-protein expression. In none of these families did IHC of other affected relatives show lack of the same gene product in tumour specimens, and genetic testing of the relevant MMR gene in blood samples did not show evidence of a pathogenic MMR mutation. The woman diagnosed with invasive endometrial cancer in the Ams? group has a distant relative (daughter of cousin) whose cancer showed lack of MSH2 and MSH6 expression. Sequencing and MLPA of these genes in a blood sample from the relative was normal, and IHC of five other relatives (including the prospective endometrial cancer) showed normal MMR expression. We cannot exclude the possibility that some of the women in the Ams? may have an MMR mutation that current techniques could not detect, or that they may carry mutations in other, yet unknown cancer-predisposing genes. We are also aware of reports on inherited methylation of the MMR genes which would have turned out as mutation negative in our series [20, 21] . None of these arguments, however, changes the overall interpretation of our findings.
Literature on prospectively observed endometrial cancer risk in AMSII families without a detectable MMR mutation is limited. Two prospective studies on endometrial cancer in women with MMR mutation and women assumed to be at increased risk based on family history have been reported [22, 23] . Forty-one women were included in the study by Rijcken et al. [22] ; of these, 27% were mutationpositive but it was not specified whether the endometrial cancer cases were among the mutation carriers. Two-hundred and sixty-nine women were included in the study by Dove-Edwin et al. [23] ; it was not mentioned how many of these were mutation carriers.
A study by considered MMR-mutation-positive women only, and used invasive techniques to detect precancers. Annual incidence rates of infiltrating cancers were not given, and were difficult to compare with our present series for methodological reasons.
It has become clear that families fulfilling AMSI or AMSII criteria may not have a detectable MMR mutation [9] [10] [11] . Studies have been performed to describe cancer risk in these families. Llor et al. [25] found that 5.1% of members of HNPCC families showing microsatellite unstable tumours were affected by endometrial cancer, compared with 3.3% of members from HNPCC families with microsatellite stable tumours. Renkonen et al. [26] found a significantly lower incidence of endometrial cancer in HNPCC families without evidence of MMR mutation compared with families with a detected MMR mutation and families with expression-based evidence of MMR mutation. We found no report in the literature to be in conflict with our conclusions. We have previously reported that adenomas in MMRmutation carriers progress more rapidly from adenoma to severe dysplasia or cancer than in AMSII kindreds without detected mutation [13] . In this work we found that increased annual incidence of endometrial cancer may be restricted to MMR-mutation-positive women. Combined, the two reports confirm that MMR-mutation carriers are more prone to both endometrial and colorectal cancers. Those without the mutations may develop both colorectal polyps and cancers later on, but do not seem to have increased risk of endometrial cancer. The presence of a significant number of endometrial cancers in retrospective series in AMSII families without a demonstrable mutation may partly reflect the selection criteria for the families reported.
Our findings support the distinction between MMRmutation carriers (Lynch syndrome) and familial CRC [14] . Colorectal and endometrial cancer is the hallmark of Lynch syndrome. A more descriptive term than the simple eponym would be ''inherited colon-endometrial cancer'' or ''the colon-endometrial cancer syndrome''. 
